Skip to content
Screener

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$142K+2.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$27K0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6K0.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0-100%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$3K+50.0%

Other financials

Income statement

See full
Revenue$92.1M+28.7%
Gross profit$79.6M+33.4%
Operating income$5.2M+15.4%
Net income-$31.1M-1,513%
EPS (diluted)-$0.18-1,700%

Balance sheet

See full
Cash & equivalents$121.7M+105%
Total debt$289.4M+12.5%
Total equity-$9.7M+49.6%
Total assets$411.9M+23.1%

Cash flow

See full
Operating cash flow$8.3M+4,440%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.45B+25.3%
Enterprise value$1.61B+19.4%
P/S4.3×-0.4×

Profitability

See full
Gross margin86.6%+4.3pp
Operating margin10.9%+8.4pp
Net margin-5.1%-1.9pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio1.4×-0.5×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001867096-26-000065
AssetsJune 30, 2026 / (unaudited)December 31, 2025
Commitments and contingencies (Note 13)
Stockholders' (deficit) equity:
Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock—par value $0.0001, 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,591,637 and 166,215,410 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1817
Additional paid in capital690,432685,004
Accumulated deficit(700,174)(671,307)
Accumulated other comprehensive loss(10)(25)
Total stockholders' (deficit) equity(9,734)13,689

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Xeris Biopharma Holdings, Inc.'s common stock?
Xeris Biopharma Holdings, Inc. (XERS) reported common stock of $18K in Q2 2026.
How has Xeris Biopharma Holdings, Inc.'s common stock changed year-over-year?
Xeris Biopharma Holdings, Inc.'s common stock increased by 12.5% year-over-year, from $16K to $18K.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s common stock?
Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s common stock has grown at a 23.2% compound annual growth rate (CAGR), from $6K to $17K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Xeris Biopharma Holdings, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude